Futura Medical

MED3000: FDA details the scope of confirmatory studyresults

Lighthouse | 22 October 2020

Share this note

  • Futura Medical has reported details of its third meeting with the FDA that firmed up the format of the six-month confirmatory study. The new trial, known as FM71, will involve c 100 patients with erectile dysfunction (ED). Around c 20 will be in the US and the balance will be similar to those who took part in the FM57 Phase III trial. The primary endpoint is efficacy against baseline assessment. The important secondary endpoints relate to speed of onset of effect and adverse events. There is no placebo and a comparison arm, using 5mg tadalafil (Cialis), will employ the same endpoints and provide an appropriate reference frame for an overall MED3000 risk/benefit analysis.
  • In the US, MED3000 is being filed as a medical device with a De Novo Classification, as there is no similar predicate device to allow a 510(k) submission. The pre-submission meetings with the FDA have confirmed the OTC (over the counter) route to market. The clinical study report (CSR), and additional clinical, safety, stability, and manufacturing information are similar to the European requirements and this technical dossier has already been collated. Development of the OTC label and associated patient information leaflet will be performed in parallel with FM71.
  • In Europe, MED3000 has been submitted for approval as a Class 2B medical device. The designated EU Notified Body has audited the QMS (Quality Management System) documentation and finished the completeness checks of the Technical Dossier. These are currently under formal review, which, in our view and COVID-19 permitting, support a regulatory approval in 2021.
  • No details of the likely cost of FM71 have been provided but this should be relatively modest (a fraction of that expected for FM57). Cash of £2.62m (at end-June 2020) provide a runway to Q221, but this does not include the costs of FM71. Management has previously stated that it could be funded by a licensing deal, debt, other non-dilutive funding, or an equity raise. Talks for the licensing rights in non-US and non-Europe regions are underway and management has a “reasonable expectation” of their completion. The upfront element of a successful deal could, in our view, fund the FM71 study.

Trinity Delta view: Futura Medical has now had three constructive meetings with the FDA that clarified MED3000’s regulatory pathway. MED3000 is expected be the first clinically proven ED product that is approved for OTC use in Europe and the US. Its rapid onset of effect, undoubted safety, and ease of use suggest MED3000 would offer an attractive, clearly differentiated, and competitive clinical profile. Whilst risks clearly remain, the discussions with the regulatory bodies have been encouraging and supportive, which suggests the inevitable pre-approval questions should be relatively straightforward and timely to address. We value Futura Medical at £153.8m, equivalent to 60.9p a share.


22 October 2020

Market Cap£33.2m
Primary exchangeAIM
Company CodeFUM
Corporate clientYes

Company description

Futura Medical is an R&D driven small pharma company, with a novel DermaSys transdermal delivery platform. The lead programme, MED3000, a topically applied gel, is being developed for erectile dysfunction (ED). A pain relief gel, TPR100, is awaiting UK approval.


Lala Gregorek
+44 (0) 20 3637 5043

Franc Gregori
+44 (0) 20 3637 5041


Trinity Delta Research Limited (“TDRL”; firm reference number: 725161), which trades as Trinity Delta, is an appointed representative of Equity Development Limited (“ED”). The contents of this report, which has been prepared by and is the sole responsibility of TDRL, have been reviewed, but not independently verified, by ED which is authorised and regulated by the FCA, and whose reference number is 185325.

ED is acting for TDRL and not for any other person and will not be responsible for providing the protections provided to clients of TDRL nor for advising any other person in connection with the contents of this report and, except to the extent required by applicable law, including the rules of the FCA, owes no duty of care to any other such person. No reliance may be placed on ED for advice or recommendations with respect to the contents of this report and, to the extent it may do so under applicable law, ED makes no representation or warranty to the persons reading this report with regards to the information contained in it.

In the preparation of this report TDRL has used publicly available sources and taken reasonable efforts to ensure that the facts stated herein are clear, fair and not misleading, but make no guarantee or warranty as to the accuracy or completeness of the information or opinions contained herein, nor to provide updates should fresh information become available or opinions change.

Any person who is not a relevant person under section of Section 21(2) of the Financial Services & Markets Act 2000 of the United Kingdom should not act or rely on this document or any of its contents. Research on its client companies produced by TDRL is normally commissioned and paid for by those companies themselves (‘issuer financed research’) and as such is not deemed to be independent, as defined by the FCA, but is ‘objective’ in that the authors are stating their own opinions. The report should be considered a marketing communication for purposes of the FCA rules. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and it is not subject to any prohibition on dealing ahead of the dissemination of investment research. TDRL does not hold any positions in any of the companies mentioned in the report, although directors, employees or consultants of TDRL may hold positions in the companies mentioned. TDRL does impose restrictions on personal dealings. TDRL might also provide services to companies mentioned or solicit business from them.

This report is being provided to relevant persons to provide background information about the subject matter of the note. This document does not constitute, nor form part of, and should not be construed as, any offer for sale or purchase of (or solicitation of, or invitation to make any offer to buy or sell) any Securities (which may rise and fall in value). Nor shall it, or any part of it, form the basis of, or be relied on in connection with, any contract or commitment whatsoever. The information that we provide is not intended to be, and should not in any manner whatsoever be, construed as personalised advice. Self-certification by investors can be completed free of charge at www.fisma.org. TDRL, its affiliates, officers, directors and employees, and ED will not be liable for any loss or damage arising from any use of this document, to the maximum extent that the law permits.

Copyright 2020 Trinity Delta Research Limited. All rights reserved.